PURPOSE: Mucopolysaccharidosis I is a genetic disorder caused by alpha-L-iduronidase deficiency. Its primary treatment is enzyme replacement therapy (ERT), which has limitations such as a high cost and a need for repeated infusions over the patient's lifetime. Considering that nanotechnological approaches may enhance enzyme delivery to organs and can reduce the dosage thereby enhancing ERT efficiency and/or reducing its cost, we synthesized laronidase surface-functionalized lipid-core nanocapsules (L-MLNC). METHODS: L-MLNCs were synthesized by using a metal complex. Size distributions were evaluated by laser diffraction and dynamic light scattering. The kinetic properties, cytotoxicity, cell uptake mechanisms, clearance profile and biodistribution were evaluated. RESULTS: Size distributions showed a D[4,3] of 134 nm and a z-average diameter of 71 nm. L-MLNC enhanced the Vmax and Kcat in comparison with laronidase. L-MLNC is not cytotoxic, and nanocapsule uptake by active transport is not only mediated by mannose-6-phosphate receptors. The clearance profile is better for L-MLNC than for laronidase. A biodistribution analysis showed enhanced enzyme activity in different organs within 4 h and 24 h for L-MLNC. CONCLUSIONS: The use of lipid-core nanocapsules as building blocks to synthesize surface-functionalized nanocapsules represents a new platform for producing decorated soft nanoparticles that are able to modify drug biodistribution.
PURPOSE:Mucopolysaccharidosis I is a genetic disorder caused by alpha-L-iduronidase deficiency. Its primary treatment is enzyme replacement therapy (ERT), which has limitations such as a high cost and a need for repeated infusions over the patient's lifetime. Considering that nanotechnological approaches may enhance enzyme delivery to organs and can reduce the dosage thereby enhancing ERT efficiency and/or reducing its cost, we synthesized laronidase surface-functionalized lipid-core nanocapsules (L-MLNC). METHODS: L-MLNCs were synthesized by using a metal complex. Size distributions were evaluated by laser diffraction and dynamic light scattering. The kinetic properties, cytotoxicity, cell uptake mechanisms, clearance profile and biodistribution were evaluated. RESULTS: Size distributions showed a D[4,3] of 134 nm and a z-average diameter of 71 nm. L-MLNC enhanced the Vmax and Kcat in comparison with laronidase. L-MLNC is not cytotoxic, and nanocapsule uptake by active transport is not only mediated by mannose-6-phosphate receptors. The clearance profile is better for L-MLNC than for laronidase. A biodistribution analysis showed enhanced enzyme activity in different organs within 4 h and 24 h for L-MLNC. CONCLUSIONS: The use of lipid-core nanocapsules as building blocks to synthesize surface-functionalized nanocapsules represents a new platform for producing decorated soft nanoparticles that are able to modify drug biodistribution.
Authors: Andressa Bernardi; Rudimar L Frozza; Ana Paula Horn; Maria Martha Campos; João B Calixto; Christianne Salbego; Adriana R Pohlmann; Sílvia S Guterres; Ana Maria O Battastini Journal: Neurochem Int Date: 2010-08-04 Impact factor: 3.921
Authors: Pascal Jonkheijm; Dirk Weinrich; Hendrik Schröder; Christof M Niemeyer; Herbert Waldmann Journal: Angew Chem Int Ed Engl Date: 2008 Impact factor: 15.336
Authors: Andressa Bernardi; Elizandra Braganhol; Eliézer Jäger; Fabrício Figueiró; Maria Isabel Edelweiss; Adriana R Pohlmann; Sílvia S Guterres; Ana M O Battastini Journal: Cancer Lett Date: 2009-03-14 Impact factor: 8.679
Authors: Rui Hong; Nicholas O Fischer; Ayush Verma; Catherine M Goodman; Todd Emrick; Vincent M Rotello Journal: J Am Chem Soc Date: 2004-01-28 Impact factor: 15.419
Authors: A Bernardi; A C C V Zilberstein; E Jäger; M M Campos; F B Morrone; J B Calixto; A R Pohlmann; S S Guterres; A M O Battastini Journal: Br J Pharmacol Date: 2009-05-06 Impact factor: 8.739
Authors: Catiúscia P Oliveira; Willian A Prado; Vladimir Lavayen; Sabrina L Büttenbender; Aline Beckenkamp; Bruna S Martins; Diogo S Lüdtke; Leandra F Campo; Fabiano S Rodembusch; Andréia Buffon; Adalberto Pessoa; Silvia S Guterres; Adriana R Pohlmann Journal: Pharm Res Date: 2016-12-15 Impact factor: 4.200
Authors: João Guilherme B De Marchi; Denise S Jornada; Fernanda K Silva; Ana L Freitas; Alexandre M Fuentefria; Adriana R Pohlmann; Silvia S Guterres Journal: Int J Nanomedicine Date: 2017-10-25
Authors: Kazuki Sawamoto; José Víctor Álvarez González; Matthew Piechnik; Francisco J Otero; Maria L Couce; Yasuyuki Suzuki; Shunji Tomatsu Journal: Int J Mol Sci Date: 2020-02-23 Impact factor: 5.923
Authors: Cecilia B Michalowski; Marcelo D Arbo; Louise Altknecht; Andréia N Anciuti; Angélica S G Abreu; Luciana M R Alencar; Adriana R Pohlmann; Solange C Garcia; Sílvia S Guterres Journal: Pharmaceutics Date: 2020-01-18 Impact factor: 6.321